Royalty Pharma plc ( RPRX) - Stock Earnings
RPRX Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q3 | 288.2 million USD | 609.3 million USD |
| 2025Q4 | 214.2 million USD | 622.0 million USD |
| 2026Q1 | 295.0 million USD | 630.6 million USD |
| 2026Q2 Est. | — | — |
| 2026Q3 Est. | — | — |
| 2026Q4 Est. | — | — |
RPRX Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | 1.1 billion USD | 2.4 billion USD |
| 2024 | 859.0 million USD | 2.3 billion USD |
| 2025 | 770.9 million USD | 2.4 billion USD |
| 2026 Est. | — | — |
RPRX
List: Challengers
Price: $54.60
Dividend Yield: 1.66%
Forward Dividend Yield: 1.71%
Payout Ratio: 56.00%
Dividend Per Share: 0.94 USD
Earnings Per Share: 1.90 USD
P/E Ratio: 27.18
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.0 million
Ebitda: -16.0 millionMarket Capitalization: 23.6 billion
Average Dividend Frequency: 4
Years Paying Dividends: 7
DGR3: 6.11%